Schmitt F A, Ashford W, Ernesto C, Saxton J, Schneider L S, Clark C M, Ferris S H, Mackell J A, Schafer K, Thal L J
University of Kentucky, Lexington, USA.
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S51-6.
Measurement of cognitive dysfunction in the early stages of Alzheimer's disease (AD) has been well studied and there are many objective tests in use for this purpose. However, with the exception of clinical rating scales, such as the Clinical Dementia Rating Scale, Global Deterioration Scale, and Functional Assessment Staging, there are few objective measures of cognition in the more advanced stages of AD. Given a renewed interest in potential AD therapies, objective measures of mental functioning are needed to adequately assess change in more advanced AD patients. As part of an effort by the NIA-Alzheimer's Disease Cooperative Study to evaluate new measures of efficacy for their utility in treatment studies, the Severe Impairment Battery (SIB) was examined in a 1-year evaluation of change across a wide range of AD severity. The data suggest that the SIB is a reliable and valid measure of progression, particularly in persons with moderate to severe AD. The SIB may therefore be a useful outcome measure in clinical trials that include patients with more advanced stages of AD.
阿尔茨海默病（AD）早期认知功能障碍的测量已得到充分研究，为此有许多客观测试可供使用。然而，除了临床评定量表，如临床痴呆评定量表、总体衰退量表和功能评估分期外，AD晚期认知功能的客观测量方法很少。鉴于对潜在AD疗法的兴趣重新燃起，需要客观的心理功能测量方法来充分评估晚期AD患者的变化。作为美国国立衰老研究所-阿尔茨海默病协作研究评估新疗效测量方法在治疗研究中的效用的一部分，严重损害成套测验（SIB）在一项为期1年的、针对广泛AD严重程度变化的评估中进行了检验。数据表明，SIB是一种可靠且有效的进展测量方法，尤其是在中度至重度AD患者中。因此，SIB可能是包括晚期AD患者在内的临床试验中一种有用的结果测量方法。
